Nephrosant
VerifiedDeveloping new diagnostic tools for early detection and lifetime monitoring of kidney health and injury.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$64—96m (Dealroom.co estimates Mar 2021.)
San Mateo California (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
$16.0m | Series A | ||
Total Funding | 000k |
Related Content
Recent News about Nephrosant
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.